Management of coagulopathy in chronic liver disease (CLD) poses a challenge for critical care physicians. Prothrombinex®-VF is a low-volume product with rapid onset of action. Evidence for its efficacy and safety in CLD is limited and cases of acute intravascular coagulation and fibrinolysis (AICF) and/or disseminated intravascular coagulation (DIC) have been reported. Our objective was to evaluate the role of Prothrombinex®-VF in reversal of coagulopathy and the incidence AICF/DIC, thromboembolic events and mortality.

中文翻译：

---

慢性肝病中的 Prothrombinex®-VF：朋友还是敌人？

慢性肝病 (CLD) 凝血病的管理对重症监护医生提出了挑战。Prothrombinex®-VF 是一种起效迅速的小批量产品。其在 CLD 中的有效性和安全性的证据有限，并且已经报道了急性血管内凝血和纤维蛋白溶解 (AICF) 和/或弥散性血管内凝血 (DIC) 的病例。我们的目标是评估 Prothrombinex®-VF 在逆转凝血病以及 AICF/DIC 发生率、血栓栓塞事件和死亡率方面的作用。